10-Q: Premier Q1 2026: Merger Progress Amidst Revenue Decline

Premier, Inc. reports a significant decrease in net income and revenue for Q1 2026, while progressing towards its acquisition by Patient Square Capital for $28.25 per share.

Summary

• Net revenue decreased by 3% to $240.0 million for the three months ended September 30, 2025, compared to $248.1 million in the prior year.
• Net income from continuing operations plummeted by 79% to $15.3 million, down from $72.9 million in the same period last year.
• Diluted earnings per share from continuing operations fell to $0.21 from $0.72 year-over-year.
• Adjusted EBITDA decreased by 12% to $54.95 million from $62.43 million.
• The company is in the process of being acquired by an affiliate of Patient Square Capital for $28.25 per share in cash, with the merger agreement signed on September 21, 2025.
• The S2S Global direct sourcing business has been fully exited as of September 30, 2025, and Contigo Health's remaining businesses are expected to be substantially wound down by December 31, 2025.
• Cash and cash equivalents decreased to $43.4 million at September 30, 2025, from $83.7 million at June 30, 2025.
• Net cash provided by operating activities from continuing operations decreased by $64.1 million to $15.9 million.

Sentiment

Score: 4

Explanation: The financial results for the quarter show significant declines in revenue, net income, and EPS, indicating operational challenges. While the pending acquisition provides a floor for the stock price, the underlying business performance is weak, particularly in the Performance Services segment. The decrease in cash from operations and the net working capital deficit are also concerning. The merger itself introduces a new set of risks.

Positives

• Supply Chain Services segment net revenue was flat year-over-year, showing resilience in its core GPO business.
• SaaS-based product subscriptions revenue increased by 6% to $41.2 million, indicating growth in a key technology area.
• Consulting services revenue increased by 10% to $21.7 million, driven by new advisory service agreements.
• The company completed its $800 million share repurchase program, returning capital to shareholders.
• The pending acquisition by Patient Square Capital at $28.25 per share provides a clear exit strategy and value for shareholders.

Negatives

• Overall net revenue decreased by 3% ($8.1 million) year-over-year.
• Net income from continuing operations significantly decreased by 79% ($57.7 million) year-over-year.
• Diluted EPS from continuing operations decreased by 71% ($0.51) year-over-year.
• Adjusted EBITDA decreased by 12% ($7.5 million) year-over-year.
• Performance Services segment net revenue decreased by 9% ($8.8 million), primarily due to a $12.4 million decrease in enterprise analytics license revenue.
• Other (expense) income, net decreased by $68.2 million, largely due to a prior year non-operating gain of $57.0 million from a shareholder derivative complaint settlement and increased interest expense.
• Net cash provided by operating activities from continuing operations decreased by $64.1 million.
• Cash and cash equivalents declined by $40.3 million during the quarter.
• The company reported a net working capital deficit of $322.8 million.

Risks

• Inability to consummate the merger with Patient Square Capital within the anticipated time period or at all, due to regulatory approvals, stockholder approval, or financing issues.
• Adverse effects on the market price of Class A Common Stock due to merger announcements.
• Disruption from the merger making it difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with members, customers, and vendors.
• Occurrence of any event, change, or circumstances that could lead to the termination of the merger agreement.
• Significant transaction costs related to the merger.
• Risk of litigation and/or regulatory actions related to the merger.
• Competition limiting the ability to maintain or expand market share.
• Reliance on administrative fees from GPO suppliers and ability to maintain/add new GPO members, influenced by competitive pressure to increase administrative fee share paid to members.
• Consolidation in the healthcare industry.
• Potential delays in recognizing or increasing revenue if sales cycles or implementation periods are longer than expected.
• Impact if GPO members reduce activity levels or terminate or elect not to renew their contracts on substantially similar terms or at all.
• Dependency of members on payments from third-party payers.
• Ability to timely offer new and innovative products and services, including the integration of artificial intelligence and the risks associated with artificial intelligence due to the evolving nature of the technology and legal and regulatory framework.
• Financial and operational risks associated with non-controlling investments in other businesses or other joint ventures that are not controlled, particularly early-stage companies.
• Data loss or corruption due to failures or errors in systems and service disruptions at data centers, or breaches or failures of security measures.
• Impact of continuing uncertain economic conditions (inflation, recessionary fears) on business operations.
• Financial and operational uncertainty due to global macroeconomic, geopolitical, and business conditions, trends and events, and the impact of any associated supply chain challenges.
• Changes and uncertainty in the political, economic, or regulatory environment affecting healthcare organizations.
• Compliance with complex international, federal, and state laws, rules and regulations governing financial relationships among healthcare providers, and the submission of false or fraudulent healthcare claims.
• Interpretation and enforcement of current or future antitrust laws and regulations.
• Compliance with complex federal, state, and international privacy, security, and breach notification laws.
• Compliance with current or future laws, rules, and regulations relating to information blocking provisions of the 21st Century Cures Act.
• Compliance with current or future laws, rules, and regulations adopted by the Food and Drug Administration applicable to software applications that may be considered medical devices.
• Adequate protection of intellectual property and potential claims against use of third-party intellectual property.
• Potential for additional indirect tax liabilities, such as gross receipts and sales and use taxes, in certain jurisdictions.
• Changes in tax laws that materially impact the tax rate, income tax expense, anticipated tax benefits, deferred tax assets, cash flows, and profitability and potential material tax disputes.
• Ability to fully realize the expected tax benefits to match the payments made under notes payable to former limited partners related to the early termination of the Unit Exchange and Tax Receivable Acceleration Agreements.
• Provisions in certificate of incorporation and bylaws and provisions of Delaware law and other applicable laws that discourage or prevent strategic transactions, including a takeover.
• Impact of stockholder activism, takeover proposals, proxy contests, or short sellers.
• Indebtedness and ability to obtain additional financing on favorable terms, including the ability to renew or replace the long-term credit facility at or before maturity.
• Fluctuation of quarterly cash flows, revenues, and results of operations.
• Failure to maintain an effective system of internal controls over financial reporting or an inability to remediate any weaknesses identified and the related costs of remediation.
• Impact on the price of Common Stock if dividends are ceased or reduced from current levels.
• Impact of new or increased tariffs on medical supplies, equipment, pharmaceuticals, and other products, potentially leading to higher procurement costs for members and other customers.

Future Outlook

The company anticipates increased demand for its Supply Chain Services and Performance Services solutions in cost management, quality and safety, and value-based care over the long-term, driven by trends in the healthcare market, inflation, and healthcare legislation. However, uncertainties and risks may affect the actual impact of these trends. The remaining businesses of Contigo Health are expected to be substantially wound down by December 31, 2025. The merger with Patient Square Capital is expected to close by March 21, 2026, subject to conditions and a possible three-month extension.

Management Comments

• We believe that we have continued to limit the impact of inflation on our members and believe that we maintain lower inflation impacts across our diverse product portfolio than national levels.
• We are continuously working to manage price increases as market conditions change.
• We continue to monitor the impacts of geopolitical tensions on macroeconomic conditions and prepare for any implications they may have on member demand, our suppliers ability to deliver products, cybersecurity risks, and our liquidity and access to capital.
• We believe that we have adequate capital resources at our disposal to fund currently anticipated capital expenditures, business growth and expansion, and current and projected debt service requirements.

Industry Context

The healthcare industry is rapidly evolving, facing increased input costs (especially labor), inflation, and potential disruptions from new healthcare legislation. There is a growing focus on scale, cost containment, and measuring/reporting financial risk for outcomes. Premier's integrated platform of solutions, including GPO, data analytics, and consulting, aims to address these demands by uniting providers, suppliers, and payers to improve healthcare quality and cost-effectiveness. The company's strategic divestitures (S2S Global, Contigo Health wrap network) and the pending acquisition by Patient Square Capital reflect a broader trend of consolidation and strategic realignment within the healthcare technology and services sector, as companies seek to optimize their portfolios and adapt to market pressures. The acquisition by a private equity firm like Patient Square Capital suggests a belief in the long-term value of Premier's core assets, potentially with a focus on operational improvements away from public market scrutiny.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks or industry standards.
• The company states it believes it maintains lower inflation impacts across its diverse product portfolio than national levels, but no specific national benchmarks are provided for comparison.
• The company mentions that some GPO competitors may offer higher revenue share arrangements to customers, indicating competitive pressure, but does not quantify this against specific industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company is periodically involved in litigation arising in the ordinary course of business, including claims related to contractual disputes, product liability, tort/personal injury, employment, antitrust, intellectual property, or other commercial/regulatory matters.
• Potential exposure to regulatory inquiries, investigations, enforcement actions, penalties, and material limitations if government regulations (e.g., antitrust, healthcare laws) are interpreted or enforced adversely.
• Historically named as a defendant in class action antitrust lawsuits by suppliers or purchasers of medical products, alleging conspiracy to deny market access, raise prices, or limit product choice. The company believes it has conducted business ethically and legally and successfully resolved such actions.
• Litigation challenging the merger agreement may be filed by purported stockholders, potentially seeking to enjoin consummation of the merger.

Related Party Transactions

• The company holds ownership interests in Prestige, Exela, and PRAM, where member health systems or their affiliates hold non-controlling interests in the consolidated subsidiaries that hold these equity method investments. These investments are part of the long-term supply chain resiliency program.
• Net income/loss attributable to non-controlling interest is recognized for non-Premier ownership in consolidated subsidiaries, including 74% and 85% interest held in PRAM and ExPre, respectively.
• As of September 30, 2025, the company owned 94% of Contigo Health, recognizing net loss attributable to non-controlling interest for the 6% equity previously issued to certain customers.

Stakeholder Impact

• Shareholders: Will receive $28.25 per share in cash if the merger with Patient Square Capital is completed, providing a defined exit value. However, they will forgo potential future appreciation in the company's value if the merger is consummated. Risks include the merger not completing or being delayed, and the stock price potentially declining if the merger fails.
• Employees: Uncertainty regarding roles, compensation, and benefits following the merger may affect retention and recruitment. Management's attention is diverted to the merger, potentially impacting day-to-day operations.
• Customers/Members: May defer decisions or seek to change existing business relationships due to uncertainty surrounding the merger. The company's mission to improve healthcare for communities remains, but the transition could impact service delivery or relationships.
• Suppliers: May be affected by potential changes in sourcing decisions and margin pressure due to tariffs, as the company works to build resiliency and diversification.
• Creditors: The company's indebtedness and ability to obtain additional financing on favorable terms are ongoing considerations, though it reports compliance with covenants and adequate capital resources for anticipated needs. The Credit Facility has a maturity date of December 12, 2027.

Next Steps

• Obtain approval of the Merger Agreement by holders of a majority of the aggregate voting power of outstanding shares of Common Stock.
• Await expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Ensure absence of any law or order by a governmental authority enjoining or prohibiting consummation of the Merger.
• Substantially wind down Contigo Health's remaining businesses by December 31, 2025.
• Address the majority of remaining GPO member agreement renewals in fiscal year 2026.
• Evaluate the impact of ASU 2025-05 (Financial Instruments Credit Losses) for its effective date in the annual reporting period beginning July 1, 2026.
• Cooperate with the IRS examination for the tax year ended June 30, 2023.
• Continue to monitor tariff developments and build resiliency within the portfolio and diversification of suppliers.
• Continue to monitor the impacts of geopolitical tensions on macroeconomic conditions.

Key Dates

Recommendation

The stock is currently subject to a definitive merger agreement at $28.25 per share. While the company's recent financial performance shows significant declines in net income and EPS, the merger provides a clear valuation floor. The primary investment consideration is the likelihood of the merger closing. Given the standard regulatory and shareholder approval conditions, there is inherent risk, but the cash offer provides a degree of certainty. A "hold" recommendation is appropriate for investors who own the stock and are awaiting the merger completion, as the upside is capped by the offer price, and the downside is limited by the offer price (assuming the merger closes). For new investors, the limited upside to the offer price, coupled with the operational declines, makes it less attractive for a "buy" unless the current market price is significantly below $28.25, offering an arbitrage opportunity. The operational challenges and risks associated with the merger's failure prevent a "strong buy" or "buy" recommendation.

Keywords

Healthcare Technology, Group Purchasing Organization, GPO, Supply Chain Services, Performance Services, Patient Square Capital, Merger, Acquisition, SEC Filing, 10-Q, Financial Results, Healthcare Analytics, Clinical Intelligence, Margin Improvement, Value-Based Care, PINC